MARKET

FUSN

FUSN

Fusion Pharmaceuticals Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.59
-0.02
-0.16%
After Hours: 12.59 0 0.00% 16:00 01/25 EST
OPEN
12.62
PREV CLOSE
12.61
HIGH
12.90
LOW
12.50
VOLUME
27.23K
TURNOVER
--
52 WEEK HIGH
19.00
52 WEEK LOW
11.21
MARKET CAP
524.55M
P/E (TTM)
-0.7119
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Fusion Pharmaceuticals (NASDAQ:FUSN) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 23h ago
Cosmo Music and Music Tribe to Enter Super Partner Relationship
CNW Group · 3d ago
/R E P E A T -- Media Advisory - CRTC to Hold a Virtual Hearing in Gatineau, Quebec/
OTTAWA, ON and GATINEAU, QC, Jan. 6, 2021 /CNW/ -WHEN:Monday, January 11, 2021 WHERE:Virtual hearing* in Gatineau TIME:10 a.
CNW Group · 01/11 12:30
TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope
TRIUMF, Canada's particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre...
GlobeNewswire · 12/16/2020 14:00
TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope
VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) -- TRIUMF, Canada’s particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company fo...
GlobeNewswire · 12/16/2020 14:00
Is FUSN A Good Stock To Buy Now?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge f...
Insider Monkey · 12/10/2020 23:24
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
CNW Group · 12/10/2020 13:10
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
Phase 1 Single-Dose Data Show Uptake Across Multiple Tumor Types; No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events
PR Newswire · 12/10/2020 13:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FUSN. Analyze the recent business situations of Fusion Pharmaceuticals Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FUSN stock price target is 23.25 with a high estimate of 25.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 25.77M
% Owned: 61.85%
Shares Outstanding: 41.66M
TypeInstitutionsShares
Increased
4
293.03K
New
31
-1.68M
Decreased
8
1.14M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.02%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
Barbara Duncan
Chief Executive Officer/Founder/Director/Primary Contact
John Valliant
Chief Scientific Officer
Eric Burak
Other
Maria Stahl
Director
Johan Christenson
Director
Eran Nadav
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FUSN
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company’s lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.
More

Webull offers kinds of Fusion Pharmaceuticals Inc stock information, including NASDAQ:FUSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FUSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FUSN stock methods without spending real money on the virtual paper trading platform.